Dayton Clinical Oncology

Phase	Trial	Trial Status	Site Status [asc]	Drug	NCT#
3	A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment	Terminated	Active	Masitinib, (AB1010)	NCT00812240